Chemoprevention of Prostate Cancer by Isoflavonoids

  • Stefan AufderklammEmail author
  • Florian Miller
  • Anastasia Galasso
  • Arnulf Stenzl
  • Georgios Gakis
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 202)


In Europe, prostate cancer (PC) is the most common malignancy in males. There are three known risk factors strongly coherent to the development of PC: heredity, ethnical origin, and age. Migration studies have shown that environmental factors may influence the development of PC. In this context, specific nutritional components may exert an influence on the tumorigenesis of PC. Primary prevention of PC is still an important issue due to its high prevalence, treatment-associated morbidities, and long-term complications. Phytoestrogenes as flavonoids seem to play an essential role in the chemoprevention of PC which is possibly due to their hormonal function and antioxidative capability. Flavonoids and their subgroups are naturally existent in traditional asian and vegetarian nutrients as coverings of plants, fruits, and vegetables. Two of the most frequently investigated flavonoids are genistein and quercetin. These nutritional components may have therapeutic potential and may impact the development of PC. Even though these flavonoids show promising results in the chemoprevention of PC, the literature is almost experimental, epidemiological, and retrospective with a missing long-term follow-up. Therefore, randomized clinical trials are urgently needed to evaluate in depth its oncologic effects in PC.


Prostate Cancer Ultra Performance Liquid Chromatography Chemopreventive Effect Prostate Cancer Incidence Lower Prostate Cancer Risk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aalinkeel R, Hu Z, Nair BB et al (2010) Genomic analysis highlights the role of the JAK-STAT signaling in the anti-proliferative effects of dietary flavonoid-‘ashwagandha’ in prostate cancer cells. J Evid Based Complementary Altern Med 7:177–187CrossRefGoogle Scholar
  2. Adams KF, Chen C, Newton KM, Potter JD, Lampe JW (2004) Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 13:644–648PubMedGoogle Scholar
  3. Banerjee S, Li Y, Wang Z, Sarkar FH (2008) Multi-targeted therapy of cancer by genistein. Cancer Lett 269:226–242PubMedCentralPubMedCrossRefGoogle Scholar
  4. Barnes S (1995) Effect of genistein on in vitro and in vivo models of cancer. J Nutr 125:777S–783SPubMedGoogle Scholar
  5. Bischoff SC (2008) Quercetin: potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care 11:733–740PubMedCrossRefGoogle Scholar
  6. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481–488PubMedCrossRefGoogle Scholar
  7. Butler LM, Wong AS, Koh WP, Wang R, Yuan JM, Yu MC (2010) Calcium intake increases risk of prostate cancer among Singapore Chinese. Cancer Res 70:4941–4948PubMedCrossRefGoogle Scholar
  8. Cheng S, Balk SP (2003) Steroid hormone receptor signaling in cancer. Cancer Treat Res 115:293–318PubMedCrossRefGoogle Scholar
  9. Cimino S, Sortino G, Favilla V et al (2012) Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev 2012:632959PubMedCentralPubMedCrossRefGoogle Scholar
  10. Czaplinska M, Czepas J, Gwozdzinski K (2012) Structure, antioxidative and anticancer properties of flavonoids. Postepy biochemii 58:235–244Google Scholar
  11. Dalais FS, Meliala A, Wattanapenpaiboon N et al (2004) Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 64:510–515PubMedCrossRefGoogle Scholar
  12. deVere White RW, Tsodikov A, Stapp EC, Soares SE, Fujii H, Hackman RM (2010) Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutr Cancer 62:1036–1043Google Scholar
  13. Egert S, Wolffram S, Bosy-Westphal A et al (2008) Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 138:1615–1621PubMedGoogle Scholar
  14. Ferris-Tortajada J, Berbel-Tornero O, Garcia-Castell J, Ortega-Garcia JA, Lopez-Andreu JA (2012) Dietetic factors associated with prostate cancer: protective effects of Mediterranean diet. Actas urologicas espanolas 36:239–245Google Scholar
  15. Gardner CD, Oelrich B, Liu JP, Feldman D, Franke AA, Brooks JD (2009) Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation. Prostate 69:719–726PubMedCentralPubMedCrossRefGoogle Scholar
  16. Gibellini L, Pinti M, Nasi M et al (2011) Quercetin and cancer chemoprevention. J Evid Based Complementary Altern Med 2011:591356Google Scholar
  17. Hussain M, Banerjee M, Sarkar FH et al (2003) Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 47:111–117PubMedCrossRefGoogle Scholar
  18. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics. CA Cancer J Clin 58:71–96PubMedCrossRefGoogle Scholar
  19. Jenster G (1999) The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 26:407–421PubMedGoogle Scholar
  20. Jin F, Nieman DC, Shanely RA, Knab AM, Austin MD, Sha W (2010) The variable plasma quercetin response to 12-week quercetin supplementation in humans. Eur J Clin Nutr 64:692–697PubMedCrossRefGoogle Scholar
  21. Key TJ, Appleby PN, Spencer EA et al (2009a) Cancer incidence in British vegetarians. Br J Cancer 101:192−197Google Scholar
  22. Key TJ, Appleby PN, Spencer EA, Travis RC, Roddam AW, Allen NE (2009b) Cancer incidence in vegetarians: results from the European Prospective Investigation into Cancer and Nutrition (EPIC-Oxford). American J Clin Nutr 89:1620S−1626SGoogle Scholar
  23. Kumar NB, Cantor A, Allen K et al (2004) The specific role of isoflavones in reducing prostate cancer risk. Prostate 59:141–147PubMedCrossRefGoogle Scholar
  24. Kumar NB, Krischer JP, Allen K et al (2007) Safety of purified isoflavones in men with clinically localized prostate cancer. Nutr Cancer 59:169–175PubMedCentralPubMedCrossRefGoogle Scholar
  25. Lazarevic B, Boezelijn G, Diep LM et al (2011) Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutr Cancer 63:889–898PubMedCrossRefGoogle Scholar
  26. Lee DH, Szczepanski M, Lee YJ (2008) Role of Bax in quercetin-induced apoptosis in human prostate cancer cells. Biochem Pharmacol 75:2345–2355PubMedCentralPubMedCrossRefGoogle Scholar
  27. Liu RH (2013) Health-promoting components of fruits and vegetables in the diet. Adv Nutr 4:384S–392SPubMedCrossRefGoogle Scholar
  28. Magee PJ, Rowland IR (2004) Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 91:513–531PubMedCrossRefGoogle Scholar
  29. Maskarinec G, Morimoto Y, Hebshi S, Sharma S, Franke AA, Stanczyk FZ (2006) Serum prostate-specific antigen but not testosterone levels decrease in a randomized soy intervention among men. Eur J Clin Nutr 60:1423–1429PubMedCrossRefGoogle Scholar
  30. McCann SE, Ambrosone CB, Moysich KB et al (2005) Intakes of selected nutrients, foods, and phytochemicals and prostate cancer risk in western New York. Nutr Cancer 53:33–41PubMedCrossRefGoogle Scholar
  31. Miyanaga N, Akaza H, Hinotsu S et al (2012) Prostate cancer chemoprevention study: an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen. Cancer Sci 103:125–130PubMedCrossRefGoogle Scholar
  32. National Cancer Institute (1996) Clinical development plan: genistein. J Cell Biochem Suppl 26:114–126 Google Scholar
  33. Pendleton JM, Tan WW, Anai S et al (2008) Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 8:132PubMedCentralPubMedCrossRefGoogle Scholar
  34. Perabo FG, Von Low EC, Ellinger J, von Rucker A, Muller SC, Bastian PJ (2008) Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis 11:6–12PubMedCrossRefGoogle Scholar
  35. Schroder FH, Roobol MJ, Boeve ER et al (2005) Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol 48:922–930; discussion 30-1Google Scholar
  36. Schultz C, Meier M, Schmid HP (2011) Nutrition, dietary supplements and adenocarcinoma of the prostate. Maturitas 70:339–342PubMedCrossRefGoogle Scholar
  37. Tang SN, Singh C, Nall D, Meeker D, Shankar S, Srivastava RK (2010) The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signaling 5:14CrossRefGoogle Scholar
  38. Tarkowski M, Kokocinska M, Latocha M (2013) Genistein in chemoprevention and treatment. Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego 34:54–57Google Scholar
  39. Travis RC, Spencer EA, Allen NE et al (2009) Plasma phyto-oestrogens and prostate cancer in the European prospective investigation into cancer and nutrition. Br J Cancer 100:1817–1823PubMedCentralPubMedCrossRefGoogle Scholar
  40. Travis RC, Allen NE, Appleby PN et al (2012) Prediagnostic concentrations of plasma genistein and prostate cancer risk in 1,605 men with prostate cancer and 1,697 matched control participants in EPIC. Cancer Causes Control 23:1163–1171PubMedCentralPubMedCrossRefGoogle Scholar
  41. Vijayababu MR, Kanagaraj P, Arunkumar A, Ilangovan R, Aruldhas MM, Arunakaran J (2005) Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. J Cancer Res Clin Oncol 131:765–771PubMedCrossRefGoogle Scholar
  42. Vijayababu MR, Arunkumar A, Kanagaraj P, Venkataraman P, Krishnamoorthy G, Arunakaran J (2006) Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). Mol Cell Biochem 287:109–116PubMedCrossRefGoogle Scholar
  43. Williamson G, Manach C (2005) Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. American J Clin Nutr 81:243S–255SGoogle Scholar
  44. Zhao R, Xiang N, Domann FE, Zhong W (2009) Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells. Nutr Cancer 61:397–407PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Stefan Aufderklamm
    • 1
    Email author
  • Florian Miller
    • 1
  • Anastasia Galasso
    • 2
  • Arnulf Stenzl
    • 1
  • Georgios Gakis
    • 1
  1. 1.Department of UrologyEberhard-Karls UniversityTübingenGermany
  2. 2.Institute of Nutritional MedicineUniversity of HohenheimStuttgartGermany

Personalised recommendations